Document Detail


Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1.
MedLine Citation:
PMID:  16204065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
DNA-damaging drugs stop tumor cell proliferation by inducing apoptosis, necrosis, or senescence. Cyclin-dependent kinase inhibitor p21waf1 is an important regulator of these responses, promoting senescence and preventing aberrant mitosis that leads to cell death. Because tumors expressing oncogenic tyrosine kinases are relatively resistant to DNA-damaging agents, the effects of Src on cellular responses to anticancer drug Adriamycin were investigated. Src expression increased drug survival in HT1080 fibrosarcoma cells, as measured by the colony formation assay, and strongly inhibited Adriamycin-induced senescence. Src also decreased the number of apoptotic cells while increasing the fraction of cells dying through necrosis. In addition, Src inhibited the G2 and G1 tetraploidy checkpoints of Adriamycin-treated cells, permitting these cells to proceed into mitosis and subsequently double their DNA content. Inhibition of senescence and G2-G1 checkpoints in Src-expressing cells was associated with the failure of these cells to up-regulate p21waf1 in response to Adriamycin. The failure of p21waf1 induction, despite increased expression of p53 and its binding to p21waf1 promoter, was mediated by the up-regulation of c-Myc, a negative regulator of p21waf1 transcription. Conversely, ectopic expression of p21waf1 inhibited Myc transcription in Src-expressing cells, an effect that was associated with the interaction of p21waf1 with the STAT3 transcription factor at the Myc promoter. These results reveal a complex effect of Src on cellular drug responses and provide an explanation for the effect of this oncogene on cellular drug resistance.
Authors:
Arnaud Vigneron; Igor B Roninson; Erick Gamelin; Olivier Coqueret
Related Documents :
20028875 - Dna damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant ...
18358095 - Antiproliferative effect of rapamycin on human t-cell leukemia cell line jurkat by cell...
6528945 - Histology of congenital nevi during the first year of life. a study by conventional and...
9584615 - Molecular mechanisms of yeast aging.
8724035 - Enhanced nuclear factor-kappa b activation induced by tumour necrosis factor-alpha in s...
22348515 - Mir-155 inhibits cell migration of human cardiomyocyte progenitor cells (hcmpcs) via ta...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  65     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-05     Completed Date:  2005-12-14     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8927-35     Citation Subset:  IM    
Affiliation:
Institut National de la Sante et de la Recherche Medicale U564, Cancer Center Paul Papin, Angers, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antineoplastic / antagonists & inhibitors*,  pharmacology
Cell Aging / drug effects
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p21 / antagonists & inhibitors,  biosynthesis*
DNA-Binding Proteins / metabolism
Down-Regulation
Doxorubicin / antagonists & inhibitors*,  pharmacology
Drug Resistance, Neoplasm
Fibrosarcoma / drug therapy*,  enzymology*,  metabolism,  pathology
G2 Phase / drug effects,  physiology
Humans
Kruppel-Like Transcription Factors
Mitosis / physiology
Polyploidy
Promoter Regions, Genetic
Proto-Oncogene Proteins c-myc / antagonists & inhibitors,  biosynthesis,  genetics
STAT3 Transcription Factor / metabolism
Transcription Factors / metabolism
Tumor Suppressor Protein p53 / metabolism
src-Family Kinases / biosynthesis,  genetics,  metabolism*
Grant Support
ID/Acronym/Agency:
R01 AG17921/AG/NIA NIH HHS; R01 CA89636/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/CDKN1A protein, human; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/DNA-Binding Proteins; 0/Kruppel-Like Transcription Factors; 0/MYC protein, human; 0/Proto-Oncogene Proteins c-myc; 0/STAT3 Transcription Factor; 0/STAT3 protein, human; 0/Transcription Factors; 0/Tumor Suppressor Protein p53; 0/ZBTB17 protein, human; 23214-92-8/Doxorubicin; EC 2.7.10.2/src-Family Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Next Document:  Decreased replication ability of E1-deleted adenoviruses correlates with increased brain tumor malig...